Viral Inactivation Global Market Size, Share, Growth, Trends, By Product Type, By Method, By Application, By End User, By Regional Forecast 2024-2033 | Sartorius AG, Texcell SA, SGS SA, Clean Cells SAS, Avantor Inc.

Spread the love

Overview and Scope
Viral inactivation refers to the process of inactivation of viral contamination by exposing the bioprocess fluid to environments that denature the viral protein yet retain the active ingredient of the product. Viral inactivation is most commonly used in blood plasma processing and monoclonal antibody processing.

Sizing and Forecast
The viral inactivation market size has grown strongly in recent years. It will grow from $4.54 billion in 2023 to $4.98 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to global air traffic growth, enhanced navigation capabilities, commercial aviation expansion, airline cost savings, improved flight safety, reduction in pilot workload.

The viral inactivation market size is expected to see rapid growth in the next few years. It will grow to $7.32 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to autonomous flight development, next-generation aircraft designs, efforts for sustainable aviation, urban air mobility (uam), increasing demand for aircraft. Major trends in the forecast period include integration of advanced avionics, implementation of artificial intelligence, human-machine interface (hmi) innovations, retrofitting existing aircraft, global navigation satellite system (gnss) integration..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

Segmentation & Regional Insights
The viral inactivation market covered in this report is segmented –
1) By Product: Kits And Reagents, Systems, Services
2) By Method: Solvent Detergent Method, pH Adjustment Method, Pasteurization, Other Methods
3) By Application: Vaccines And Therapeutics, Tissues And Tissue Products, Blood And Blood Products, Other Applications
4) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Blood Banks, Hospital, Academic Research Institutes, Other End Users

North America was the largest region in the viral inactivation market in 2023. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10401&type=smp

Major Driver Impacting Market Growth
Growing instances of various infectious diseases are expected to propel the growth of the viral inactivation market, going forward. Infectious diseases refer to the conditions that transmit from one individual to another, via polluted foods and beverages, and through pathogens such as viruses, bacteria, fungi, and parasites. Viral inactivation is widely applicable in human disease-control programs to inactivate viruses using physical and chemical disinfectants to prevent the spread of contagious viral infections, resulting in the growth of the viral inactivation market. For instance, in December 2022, according to the ‘Annual Epidemiological Report for 2021’, published by European Centre for Disease Prevention and Control, a Sweden-based, European Government Health Agency, 2021, the distribution of hepatitis C cases and rates per 100,000 population, in Germany, reached 4,718 cases and 5.7 rates respectively from 4,536 cases 5.5 rates in 2020. Therefore, the growing instances of various infectious diseases are driving the growth of the viral inactivation market.

Key Industry Players
Major companies operating in the viral inactivation market report are Merck & Co. Inc., PARKER HANNIFIN CORP., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Shandong Weigao Group Medical Polymer Co. Ltd., SCI Automation Pte. Ltd., Pall Corporation And Eurofins Scientific, General Electric Company, Cytiva, Mettler Toledo, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Pfizer Inc., Novartis AG, Gilead Sciences Inc., Johnson & Johnson Private Limited

The viral inactivation market report table of contents includes:
1. Executive Summary